Envirotainer, the global market leader in secure cold chain solutions for shipment of pharmaceuticals, has opened a new CryoSure station in Singapore. This significantly expands global availability of the ultra-cold solution for the transportation of medicines at -70°C.
The station sits near one of the largest airports in the world for international cargo traffic and a major hub for Asia and Pacific (APAC). This puts -70°C cryogenic shipping within reach of the fastest growing region in the pharmaceutical logistics market.
The new site complements Envirotainer’s existing presence in Singapore, ensures high global service levels and allows express orders throughout APAC.
CryoSure is suitable for many ultra-cold chain uses such as cell and gene therapies, one of the fastest growing markets in the life sciences sector. Designed with extreme demands in mind, the solution comprises a range of dewars with unmatched performance and superior duration of up to three weeks without the need for refilling dry ice. They’re heat resistant with unparalleled ease-of-use, which further mitigates risk. It’s the most reliable choice for cryogenic -70°C shipments.
With this new addition to Envirotainer’s broad global network, customers will benefit from more efficient logistics. It not only improves the offering for customers in terms of speed and availability, but also sustainability.
CryoSure is the most sustainable solution of its type on the market. The reusable dewars are noticeably less bulky than others and have two to three times better weight to volume efficiency compared to existing dry-ice boxes and liquid nitrogen (LN2) solutions. This translates into both significantly reduced transportation costs, as well as significantly lower carbon emissions.
Moving products at below -70°C is very challenging. Long journeys, combined with the risk of delays, human error and challenges with the supply and handling of dry ice can put shipments at risk. There is no room for failure when life-saving products need delivery.
With CryoSure now available on a global scale, it will be possible to ensure vital treatments can be where and when needed quickly in most of Europe, North America and Asia. Expansion of the network will continue.
